Korro Bio, Inc.

NASDAQ•KRRO

CEO: Mr. Nessan Bermingham Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2019-10-03

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Contact Information

One Kendall Square, Building 600-700 Suite 6-401, Cambridge, MA, 02139, United States

617-468-1999

www.korrobio.com

Market Cap

$108.11M

P/E (TTM)

-1.2

17.5

Dividend Yield

52W High

$55.89

52W Low

$5.20

52W Range

12%

Rank59Top 87.6%

2.2

F-Score

Modified Piotroski Analysis

Based on 8-year fundamentals

Weak • 2.2 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2018-2025

Financial Dashboard

Q3 2025 Data

Revenue

$1.09M+0.00%

4-Quarter Trend

EPS

-$1.92-15.04%

4-Quarter Trend

FCF

-$17.35M-17.26%

4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Collaboration Revenue Recognized Nine months collaboration revenue reached $5.1M, compared to zero recognized in the prior nine months period.

R&D Expenses Increased Research and development expenses rose $7.9M to $54.6M for nine months, funding pipeline advancement.

KRRO-121 Candidate Nominated Nominated KRRO-121 for UCD/HE treatment; planning first-in-human regulatory filing in second half 2026.

Cash Runway Extended Cash, cash equivalents, and marketable securities totaled $102.5M, funding operations into second half 2027.

Risk Factors

KRRO-110 Program Pivoting KRRO-110 failed to meet AATD protein goals; pivoting delivery method, which may cause development delays.

Increased Net Loss Nine months net loss widened to $67.2M from $62.4M; requires substantial future capital infusion.

Workforce Reductions Impact Implemented two workforce reductions (May and November 2025); future expansion efforts face integration challenges.

Novo Nordisk Collaboration Paused Novo Nordisk collaboration paused for 12 months starting November 2025, suspending expected revenue recognition.

Outlook

KRRO-121 Clinical Trial Filing Plan to submit regulatory filing for KRRO-121 first-in-human trial during the second half of 2026.

AATD Candidate Nomination Prioritizing GalNAc-conjugated AATD program; expect to nominate a development candidate during 2026.

Continued High R&D Spending Expect substantial increase in R&D expenses to advance pipeline through clinical development stages.

Pursuing Additional Financing Will pursue additional cash resources through public or private equity offerings, collaborations, or debt financings.

Peer Comparison

Revenue (TTM)

AMRN

$183.87M

-19.6%

CLLS

$75.27M

+158.9%

ADCT

$73.55M

+3.8%

Gross Margin (Latest Quarter)

ALT

57207.7%

-299200.0pp

AMRN

119.2%

+7.3pp

KRRO

100.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
RAPT	$959.26M	-14.8	-61.8%	1.6%
ANNX	$727.14M	-4.4	-92.3%	11.8%
ADCT	$594.61M	-5.1	66.2%	135.9%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-21.7%

Growth Under Pressure

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Mar 17, 2026

EPS:-$1.93

Revenue:$425.00K

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data